366-70-1

• 常用中文名：盐酸甲基苄肼
• 常用英文名：Procarbazine hydrochloride
• CAS号：366-70-1
• 分子式：C₁₂H₂₀ClN₃O
• 分子量：257.760
• 相关类别： 生物化工 抑制剂 DNA损伤(DNA Damage) DNA/RNA Synthesis 抑制剂
• 发布时间：2018-08-31 20:19:29
• 更新时间：2024-01-02 21:42:34
• Procarbazine Hydrochloride 是一种烷化剂 (alkylator),具有抗肿瘤的作用。

名称

• 中文名: 盐酸甲基苄肼
• 英文名: procarbazine hydrochloride
• 中文别名: N-异丙基-4-((2-甲基肼)甲基)苯甲酰胺盐酸盐; 甲基苄肼盐酸盐
• 英文别名: N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide hydrochloride (1:1); 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide,hydrochloride; N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride; MFCD00072082; Procarbazine hydrochloride; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide hydrochloride (1:1); benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-, monohydrochloride; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazinyl)methyl]-, hydrochloride (1:1); Procarbazine HCl; EINECS 206-678-6; p-Toluamide, N-isopropyl-α- (2-methylhydrazino)-, monohydrochloride; Procarbazine (Hydrochloride)

物化性质

• 沸点: 384.6ºC at 760 mmHg
• 熔点: 223ºC
• 分子式: C₁₂H₂₀ClN₃O
• 分子量: 257.760
• 闪点: 148.9ºC
• 精确质量: 257.129486
• PSA: 53.16000
• LogP: 3.02350
• 外观性状: 白色至淡黄色结晶粉末
• 储存条件: -20°C Freezer
• 水溶解性: >=10 g/100 mL at 21.5 ºC

生物活性

• 描述: Procarbazine Hydrochloride 是一种烷化剂 (alkylator),具有抗肿瘤的作用。
• 相关类别:
  信号通路 >> 细胞周期/DNA损伤 >> DNA烷基化剂/交联剂
  研究领域 >> 癌症
• 体外研究: Procarbazine Hydrochloride是一种抗癌剂。 Procarbazine对缺乏细胞色素P-450或单胺氧化酶活性的LI 210细胞没有细胞毒性[1]。
• 体内研究: 盐酸丙卡巴肼(50mg/kg,ip)在造血细胞中引起微核,但不增加小鼠骨髓中的lacZ突变频率(MF),类似于肝,睾丸,脾,肾和肺中的那些。盐酸丙卡巴肼(50 mg/kg,ip)对肺癌,骨髓和脾脏有致癌作用[2]。 Procarbazine(450 mg/kg)显着降低睾丸和附睾重量,并显着减少单倍体细胞和仓鼠中的生精停滞[3]。
• 细胞实验: 在丙卡巴肼或代谢物处理后，将细胞在25-cm 2培养瓶（10mL）中稀释至50.000 / mL。每24小时，取出0.5-mL等分试样，在Hematall等渗稀释剂中稀释20倍，并用Coulter Model F电子细胞计数器测定细胞数。大于10,000 / 0.5 mL的计数校正重合。当细胞密度超过1×106 / mL时，细胞在新鲜培养基中稀释。保持培养物直至聚集细胞数接近100×106 / mL并且倍增时间恢复至12小时。使用方程式A确定细胞存活，其中TD（感兴趣的细胞的倍增时间）是12小时[1]。
• 动物实验: 小鼠[2]在适应2周后使用雄性MutaTM小鼠动物（7-8周龄）。在第一个实验中，18只小鼠腹膜内（ip）注射50mg / kg盐酸丙卡巴肼10mL盐水/ kg，8只小鼠注射10mL盐水/ kg作为媒介物对照。处理后7,14和28天处死6只处理过的小鼠，处理后7天和28天处死4只对照小鼠。杀死是由颈椎脱位[2]。
• 参考文献:

  [1]. Erikson JM, et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res. 1989 Jan 1;49(1):127-33.

  [2]. Suzuki T, et al. Procarbazine genotoxicity in the MutaMouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res. 1999 Aug 18;444(2):269-81.

  [3]. Weissenberg R, et al. Procarbazine effects on spermatogenesis in golden hamster: a flow cytometric evaluation. Arch Androl. 2002 Mar-Apr;48(2):91-100.

MSDS

Section1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE Product identifiers Product name: Procarbazine Hydrochloride CAS-No.: 366-70-1 Relevant identified uses of the substance or mixture and uses advised against Identified uses: Laboratory chemicals, Manufacture of substances Section2. HAZARDS IDENTIFICATION Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP] Acute toxicity, Oral (Category 4) Germ cell mutagenicity (Category 2) Carcinogenicity (Category 1B) Reproductive toxicity (Category 1A) Classification according to EU Directives 67/548/EEC or 1999/45/EC Harmful if swallowed. May cause cancer. May cause harm to the unborn child. Possible risk of irreversible effects. Label elements Labelling according Regulation (EC) No 1272/2008 [CLP] Pictogram Signal wordDanger Hazard statement(s) H302Harmful if swallowed. H341Suspected of causing genetic defects. H350May cause cancer. H360May damage fertility or the unborn child. Precautionary statement(s) P201Obtain special instructions before use. P281Use personal protective equipment as required. P308 + P313IF exposed or concerned: Get medical advice/ attention. Supplemental Hazardnone Statements Restricted to professional users. According to European Directive 67/548/EEC as amended. Hazard symbol(s) R-phrase(s) R45May cause cancer. R61May cause harm to the unborn child. R22Also harmful if swallowed. R68Possible risk of irreversible effects. S-phrase(s) S36/37Wear suitable protective clothing and gloves. S45In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). S53Avoid exposure - obtain special instructions before use. Restricted to professional users. Other hazards - none Section3. COMPOSITION/INFORMATION ON INGREDIENTS Substances Synonyms: N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride Formula: C12H19N3O·HCl Molecular Weight: 257,76 g/mol ComponentConcentration PROCARBAZINE HYDROCHLORIDE CAS-No.366-70-1- EC-No.206-678-6 Section4. FIRST AID MEASURES Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Flush eyes with water as a precaution. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. Most important symptoms and effects, both acute and delayed Blood disorders, Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhoea., Exposure can cause numbness, tingling, and weakness in extremities. Indication of any immediate medical attention and special treatment needed no data available Section5. FIREFIGHTING MEASURES Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture no data available Advice for firefighters Wear self contained breathing apparatus for fire fighting if necessary. Further information no data available Section6. ACCIDENTAL RELEASE MEASURES Personal precautions, protective equipment and emergency procedures Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Environmental precautions Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Methods and materials for containment and cleaning up Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for disposal. Reference to other sections For disposal see section 13. Section7. HANDLING AND STORAGE Precautions for safe handling Avoid exposure - obtain special instructions before use.Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Recommended storage temperature: 2 - 8 °C Specific end uses no data available Section8. EXPOSURE CONTROLS/PERSONAL PROTECTION Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Personal protective equipment Eye/face protection Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Body Protection Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Section9. PHYSICAL AND CHEMICAL PROPERTIES Information on basic physical and chemical properties a) AppearanceForm: liquid b) Odourno data available c) Odour Thresholdno data available d) pHno data available e) Melting point/freezingno data available point f) Initial boiling point and no data available boiling range g) Flash pointno data available h) Evaporation rateno data available i) Flammability (solid, gas) no data available j) Upper/lowerno data available flammability or explosive limits k) Vapour pressureno data available l) Vapour densityno data available m) Relative densityno data available n) Water solubilityno data available o) Partition coefficient: n- no data available octanol/water p) Autoignitionno data available temperature q) Decompositionno data available temperature r) Viscosityno data available s) Explosive propertiesno data available t) Oxidizing propertiesno data available Other safety information no data available Section10. STABILITY AND REACTIVITY Reactivity no data available Chemical stability no data available Possibility of hazardous reactions no data available Conditions to avoid no data available Incompatible materials Strong oxidizing agents Hazardous decomposition products Other decomposition products - no data available Section11. TOXICOLOGICAL INFORMATION Information on toxicological effects Acute toxicity LD50 Oral - rat - 570 mg/kg LD50 Oral - mouse - 560 mg/kg LD50 Intravenous - rat - 350 mg/kg LD50 Subcutaneous - rat - 490 mg/kg LD50 Intraperitoneal - mouse - 699 mg/kg LD50 Intravenous - mouse - 540 mg/kg LD50 Subcutaneous - mouse - 710 mg/kg Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitization no data available Germ cell mutagenicity In vitro tests showed mutagenic effects Carcinogenicity Possible human carcinogen IARC:2A - Group 2A: Probably carcinogenic to humans (PROCARBAZINE HYDROCHLORIDE) Reproductive toxicity Known human reproductive toxicant Specific target organ toxicity - single exposure no data available Specific target organ toxicity - repeated exposure no data available Aspiration hazard no data available Potential health effects InhalationMay be harmful if inhaled. May cause respiratory tract irritation. IngestionHarmful if swallowed. Skin May be harmful if absorbed through skin. May cause skin irritation. EyesMay cause eye irritation. Signs and Symptoms of Exposure Blood disorders, Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhoea., Exposure can cause numbness, tingling, and weakness in extremities. Additional Information RTECS: Not available Section12. ECOLOGICAL INFORMATION Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment no data available Other adverse effects no data available Section13. DISPOSAL CONSIDERATIONS Waste treatment methods Product Offer surplus and non-recyclable solutions to a licensed disposal company. Contaminated packaging Dispose of as unused product. Section14. TRANSPORT INFORMATION UN number ADR/RID: -IMDG: -IATA: - UN proper shipping name ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA:Not dangerous goods Transport hazard class(es) ADR/RID: -IMDG: -IATA: - Packaging group ADR/RID: -IMDG: -IATA: - Environmental hazards ADR/RID: noIMDG Marine pollutant: noIATA: no Special precautions for user no data available SECTION 15 - REGULATORY INFORMATION N/A SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XS4725000 CHEMICAL NAME : p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, monohydrochloride CAS REGISTRY NUMBER : 366-70-1 LAST UPDATED : 199710 DATA ITEMS CITED : 111 MOLECULAR FORMULA : C12-H19-N3-O.Cl-H MOLECULAR WEIGHT : 257.80 WISWESSER LINE NOTATION : 1Y1&MVR D1MM1 &GH HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 570 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - lacrimation Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - dyspnea TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 490 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 350 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 785 mg/kg TOXIC EFFECTS : Blood - leukopenia Blood - thrombocytopenia Immunological Including Allergic - decreased immune response TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 560 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 699 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 710 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 540 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1320 mg/kg TOXIC EFFECTS : Blood - leukopenia Blood - thrombocytopenia Immunological Including Allergic - decreased immune response TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 145 mg/kg TOXIC EFFECTS : Blood - leukopenia Blood - thrombocytopenia Immunological Including Allergic - decreased immune response TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2700 mg/kg/5W-I TOXIC EFFECTS : Endocrine - changes in spleen weight Related to Chronic Data - death Related to Chronic Data - changes in ovarian weight TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2100 mg/kg/5W-I TOXIC EFFECTS : Endocrine - changes in spleen weight Related to Chronic Data - death Related to Chronic Data - changes in ovarian weight TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 500 mg/kg TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - tumors Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1170 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Brain and Coverings - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors Endocrine - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 125 mg/kg female 22 day(s) after conception TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - transplacental tumorigenesis Brain and Coverings - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2 gm/kg/8W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - leukemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2340 mg/kg/42W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Brain and Coverings - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 4088 mg/kg/5Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Multiple routes SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 3270 mg/kg/69W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia Musculoskeletal - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 4680 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease Skin and Appendages - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1950 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 500 mg/kg TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - tumors Skin and Appendages - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1136 mg/kg/8W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - leukemia TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4680 mg/kg/52W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Brain and Coverings - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2340 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Brain and Coverings - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Multiple routes SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 20 gm/kg/8Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia Musculoskeletal - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1200 mg/kg/14W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Skin and Appendages - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2560 mg/kg/8W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - leukemia TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2 gm/kg/8W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - leukemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 120 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : female 1-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 120 mg/kg SEX/DURATION : female 1-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - abortion TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 4 mg/kg SEX/DURATION : female 13-16 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 360 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 30 mg/kg SEX/DURATION : female 12-15 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 800 mg/kg SEX/DURATION : male 4 week(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 2100 mg/kg SEX/DURATION : male 30 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : female 7-9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - Central Nervous System TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : female 7-9 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 120 mg/kg SEX/DURATION : female 8-13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 360 mg/kg SEX/DURATION : female 8-13 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 2100 mg/kg SEX/DURATION : female 30 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 200 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 100 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 400 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 200 mg/kg SEX/DURATION : female 14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - homeostasis TYPE OF TEST : Sex chromosome loss and nondisjunction TYPE OF TEST : DNA damage TYPE OF TEST : DNA inhibition TYPE OF TEST : Unscheduled DNA synthesis TYPE OF TEST : DNA inhibition TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : Specific locus test TYPE OF TEST : Specific locus test TYPE OF TEST : DNA damage TYPE OF TEST : Cytogenetic analysis TYPE OF TEST : Cytogenetic analysis TYPE OF TEST : Sister chromatid exchange TYPE OF TEST : Dominant lethal test TYPE OF TEST : Dominant lethal test TYPE OF TEST : Mutation in mammalian somatic cells TYPE OF TEST : Sperm Morphology TYPE OF TEST : Sister chromatid exchange MUTATION DATA TEST SYSTEM : Mammal - pig DOSE/DURATION : 168 mg/kg/4W (Continuous) REFERENCE : CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 13,2153,1992 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,311,1981 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,311,1981 IARC Cancer Review:Group 2A IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,327,1987 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4523 No. of Facilities: 32 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1328 (estimated) No. of Female Employees: 289 (estimated)

安全

• 符号: GHS07, GHS08
• 信号词: Danger
• 危害声明: H302-H341-H350-H360
• 警示性声明: P201-P280-P301 + P312 + P330-P308 + P313
• 危害码 (欧洲): T
• 风险声明 (欧洲): 45-61-22-68
• 安全声明 (欧洲): 53-36/37-45
• 危险品运输编码: NONH for all modes of transport
• 海关编码: 2928000090

海关

海关编码	2928000090
中文概述	2928000090 其他肼（联氨）及胲（羟胺）的有机衍生物。监管条件:无。增值税率:17.0%。退税率:9.0%。最惠国关税:6.5%。普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%